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Mixed donor chimerism is increasingly common in the pediatric hematopoietic stem cell transplantation
(HSCT) setting because of the increased use of reduced-intensity preparative regimens for nonmalignant
diseases. Donor lymphocyte infusion (DLI) is potentially useful in the treatment of mixed donor chimerism,
but little are data available on the use of DLI in this setting. We conducted a retrospective review of 27
pediatric patients who received DLI for mixed donor chimerism between January 2006 and December 2010
after receiving a preparative regimen of alemtuzumab, ﬂudarabine, and melphalan. Twenty-one patients
(78%) were alive at a median of 35 months post-transplant. Seven patients (26%) sustained full donor
chimerism after DLI only at a median of 35 months post-HSCT. Nine patients (33%) continued with mixed
donor chimerism (median, 38% [range, 18% to 70%]) at a median of 37 months after DLI only. Five patients
underwent unconditioned stem cell boosts or second conditioned transplants after no improvement in donor
chimerism was seen following DLI. Donor source appeared to contribute to outcomes after DLI; patients with
mismatched unrelated donors had earlier ﬁrst decline in chimerism and timing of ﬁrst DLI, a higher response
rate to DLI, and an increased rate of graft-versus-host disease (GVHD). There was no response to DLI in pa-
tients with matched sibling donors. Ten patients, all with improvement in chimerism after DLI, developed
acute GVHD after DLI, with 3 having grade III GVHD. Three patients developed chronic GVHD after DLI. These
data illustrate the potential efﬁcacy of DLI in the treatment of mixed donor chimerism after a reduced-
intensity preparative regimen.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Mixed donor chimerism, the coexistence of donor and
recipient hematopoiesis after allogeneic stem cell trans-
plantation, is increasingly seen in the pediatric setting
because of the upsurge in use of reduced-intensity condi-
tioning regimens for nonmalignant diseases. Mixed donor
chimerism is associated with a decreased risk of graft-
versus-host disease [1-5], but patients with mixed donor
chimerism are at increased risk for graft loss and recurrence
of the original disease [4]. Factors contributing to the
development of mixed donor chimerism include the pa-
tient’s underlying diagnosis, the composition and dose of the
cell graft, and the intensity of the preparative regimen and
use of serotherapies that deplete graft lymphocytes [6,7].edgments on page 292.
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ty for Blood and Marrow Transplantation.Although full donor chimerism is necessary to cure most
malignant conditions, it is now apparent that partial donor
chimerism is sufﬁcient to eradicate the manifestations of
many nonmalignant diseases, particularly immunodeﬁ-
ciencies and hemoglobinopathies [6,8,9]. With hemopha-
gocytic lymphohistiocytosis, a patient may display no
evidence of the original disease with a donor chimerism as
low as 20% [6]. The decreased mortality and late effects of
reduced-intensity preparative regimens are especially
attractive in the treatment of diagnoses inwhich the patient
population is predominantly pediatric and full donor
chimerism is not required. Speciﬁcally, Marsh et al. [6] and
Cooper et al. [8] reported improved outcomes when using a
reduced-intensity preparative regimen for hemophagocytic
lymphohistiocytosis. However, the decreased toxicity of
reduced-intensity preparative regimens is traded for an
increased risk of nonengraftment, mixed donor chimerism,
and graft loss.
Table 1
Transplant Characteristics of Patients Undergoing DLI for Mixed Donor
Chimerism
Characteristic All Patients
Diagnosis
Hemophagocytic lymphohistiocytosis 16
Severe combined immunodeﬁciency 3
Omenn’s syndrome 1
X-linked lymphoproliferative disease 3
Common variable immunodeﬁciency 1
Hurler’s syndrome 1
Langerhans cell histiocytosis 1
IPEX 1
Sex
Male 20
Female 7
Donor source
Matched sibling bone marrow 4
8/8 unrelated donor 14
7/8 unrelated donor 8
6/8 unrelated donor 1
Median age at transplant, yr (range) 1.2 (.31-17)
Preparative regimen
Proximal alemtuzumab 21
Distal alemtuzumab 6
IPEX indicates Immune Dysregulation, polyendocrinopathy, enteropathy, X-
linked.
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modulation via taper of immunosuppression and donor
lymphocyte infusion (DLI) because of the concern for graft
loss [10-13]; however, both treatments increase the risk for
graft-versus-host disease (GVHD). Currently, very little data
are found in the literature on outcomes after DLI for mixed
donor chimerism to help guide the physician in managing
this complication. In this retrospective study we investigated
the characteristics and outcome of patients who received DLI
for nonmalignant disease after a reduced-intensity prepar-
ative regimen of alemtuzumab, ﬂudarabine, and melphalan.
To our knowledge, this is the ﬁrst study in a relatively large
pediatric cohort detailing the use and outcomes of DLI for
management of mixed donor chimerism after reduced-
intensity preparative regimens composed of predominantly
pediatric patients with nonmalignant diseases.
METHODS
A retrospective review was conducted on all patients who received DLIs
between January 2006 and December 2010. Patients were included in this
series if they received DLIs for mixed donor chimerism after a preparative
regimen of alemtuzumab, ﬂudarabine, and melphalan.
Patients and Transplant Characteristics
Timing and dose of alemtuzumab was based on physician preference.
Most patients received proximal alemtuzumab, with dosing starting any-
where from day 12 to day 7. Six patients received distal alemtuzumab
with dosing starting before day20. Most patients received ﬂudarabine 150
mg/m2 andmelphalan 140mg/m2. All patients received bonemarrow grafts.
In 25 patients, GVHD prophylaxis consisted of cyclosporine or tacrolimus
and methylprednisolone 1 to 2 mg/kg/day with planned methylpredniso-
lone taper starting day 28 in the absence of mixed chimerism or GVHD. One
patient received GVHD prophylaxis with mycophenolate and prednisone,
and 1 received cyclosporine, methylprednisolone and methotrexate with
methotrexate dosed on days þ1, þ3, and þ6. Table 1 shows patient and
transplant characteristics.
Donor Chimerism Measurement
Whole blood total donor chimerism was monitored frequently (most
commonly weekly) from the time of engraftment. In patients with opposite
sex donors, chimerism was monitored by ﬂuorescent in situ hybridization
with X and Y chromosome probes. In patients with same-sex donors, donor
chimerismwasmonitored with PCR ampliﬁcation of 15 highly variable short
tandem repeats followed by capillary electrophoresis for size discrimination
to determine the various alleles at 15 individual loci aswell as chromosomeXand Y speciﬁc products. Chimerism sorted by cell subsets was not routinely
obtained butwas performedwhen clinically indicated at the discretion of the
attending physician. All whole blood chimerism studies were performed in
the clinical genetics laboratory at Cincinnati Children’s Hospital.
Donor Lymphocyte Infusion
Decisions to give DLIs, dose of DLIs, and timing of DLIs, were not pre-
scribed and were at the discretion of the attending physician. Lymphocytes
for DLI were either frozen aliquots collected from the donor at the time of
the original harvest or were collected peripherally from the donor before
DLI.
Deﬁnitions and Outcomes
Complete response to DLI was deﬁned as a donor chimerism of 98% to
100%. Response to DLI was deﬁned as a donor chimerism increase of at least
20% after DLI. Loss of donor chimerism was deﬁned as a decrease of at least
10% from peak donor chimerism after hematopoietic stem cell trans-
plantation (HSCT). Descriptive statistics were used to look for outliers and
assess distributional properties.
The Mann-Whitney U test and exact Kruskal-Wallis test were used to
examine the differences between groups. Variables examined were days
post-transplant for ﬁrst decreased engraftment, days post-transplant for
ﬁrst DLI, last engraftment before ﬁrst DLI, age at ﬁrst DLI, and number of
DLIs. Results are presented as medians with ranges and P values where
appropriate. Logistic regressionwas used to test if intervention timing was a
signiﬁcant predictor of complete response versus no complete response.
Because of the small patient numbers and descriptive nature of the study, no
adjustments were made for multiple testing.
Analyses were performed using SAS statistical software package, version
9.3 (SAS Institute, Inc., Cary, NC). Signiﬁcance was set a priori at a ¼ .05.
Acute and chronic GVHD were assessed and classiﬁed by standardized
published criteria [14,15].
RESULTS
Patients
One hundred twenty-six patients underwent transplant
for nonmalignant disease with a preparative regimen of
alemtuzumab, ﬂudarabine, and melphalan from 2006 to
2010. Of these 126 patients, 27 (21.4%) received DLI for mixed
donor chimerism after having no improvement in chimerism
with immunosuppression taper. The patients who developed
mixed donor chimerism but did not receive DLI were not
included in this series.
Institutional Approach to Management of Mixed Donor
Chimerism
Because management of waning donor chimerism was
not prescribed, there was some heterogeneity in treatment;
however, there was broad institutional agreement on the
approach to mixed donor chimerism. Initial management of
waning donor chimerismwas generally a rapid taper (over 1
to 2 weeks) or abrupt discontinuation of corticosteroids,
followed by taper of calcineurin inhibitors. In the absence of
GVHD, DLI followedwithin 3 or 4weeks of discontinuation of
immunosuppression if there was not stabilization of donor
chimerism. The rate at which physicians moved through
these interventions varied, with donor source, level and rate
of decline of donor chimerism, underlying disease, and his-
tory of GVHD among the variables contributing to the deci-
sion. In the absence of GVHD, patients who did not achieve
stabilization or improvement in donor chimerism generally
received subsequent DLIs with escalating dose of T cells at
the discretion of the attending physician.
General Characteristics of DLI Therapy
Twenty-seven patients received a total of 88 DLIs. The
ﬁrst DLI was given at a median of 98 days post-transplant
(range, 44 to 230). Other characteristics of DLI are dis-
played in Table 2. Patients received amedian of 2 DLIs (range,
1 to 12) with a median interval between infusions of 21 days
Table 2
Characteristics of DLI Therapy
All Patients
(n ¼ 27)
Matched Sibling
Donors (n ¼ 4)
Matched Unrelated
Donors (n ¼ 14)
Mismatched Unrelated
Donors (n ¼ 9)
P*
Days post-transplant for ﬁrst DLI 98 (44-230) 143.5 (97-230) 117.5 (44-188) 62 (46-188) .099
Median ﬁrst T cell dose (106 CD3/kg) 1.0 (.02-20) 3.0 (.5-11) 1.0 (.02-10) 2.0 (.2-20) .585
Median max T cell dosey (106 CD3/kg) 4.6 (.2-421) 8.0 (4.1-200) 27.5 (.2-421) 2.0 (.2-20) .084
Median total T cell dose (106 CD3/kg) 4.5 (.2-372) 22.6 (5-372) 44 (.2-352.1) 2.0 (.2-20) .039
Days post-transplant for ﬁrst loss of donor chimerism 47 (19-118) 62 (47-77) 48 (19-118) 31 (22-51) .070
Days post loss of chimerism for ﬁrst DLI 45 (16-157) 88 (38-153) 49.5 (25-155) 30 (16-157) .209
Last chimerism before starting DLI 41 (9-74.2) 55 (41-70.8) 46 (10-69) 34.8 (9-74.2) .117
Median number of DLIs 2 (1-12) 4 (1-12) 4 (1-8) 1 (1-2) .017
Values are medians, with min-max in parentheses.
* Unadjusted P values shown; no adjustment made for multiple testing due to small numbers.
y In patients receiving more than 1 DLI.
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the remaining patients received multiple DLIs, with 10 pa-
tients receiving 5 or more. Median donor chimerism before
DLI was 41% (range, 9% to 74%).
Chimerism Response after DLI
Individual patient responses to DLI are detailed in Table 3.
Graphs illustrating individual patient chimerism and timingTable 3
Long-Term Outcomes after DLI
Patient
Number
Diagnosis Donor Source Timing of
Alemtuzumab
GVHD
after DLI
Chimerism
at First DLI
Pe
af
1*,y HLH MSD Proximal 68 7
2*,y XLP MSD Proximal 70.8 5
3*,y HLH MSD Proximal 41 5
4*,y HLH MSD Proximal 42 3
5*,y HLH MUD Proximal 69 9
6*,y XLP MUD Proximal 55 10
7 LCH MUD Proximal 55 4
8* HLH MUD Distal 41 10
9 Hurler’s MUD Distal 65 3
10* HLH MUD Proximal 22 3
11*,y HLH MUD Distal 48 7
12 SCID MUD Proximal 38 3
13*,y HLH MUD Proximal III (GI) 59 10
14 SCID MUD Distal I (skin) 41 6
15*,y HLH MUD Proximal 49.6 5
16*,y HLH MUD Proximal I (skin) 10 10
17 CVID MUD Distal II (skin) 61.6 10
18*,y HLH MUD Proximal 11.2 2
19*,y XLP MMUD (7/8) Proximal II (skin) 31 9
20*,y HLH MMUD (7/8) Distal III (liver) 34.8 10
21y HLH MMUD (7/8) Proximal III (skin/GI) 39 9
22y HLH MMUD (7/8) Proximal 29 3
23 IPEX MMUD (7/8) Proximal 37.5 2
24 Omenn’s MMUD (7/8) Proximal II (skin) 14 9
25*,y HLH MMUD (7/8) Proximal 9 3
26y HLH MMUD (7/8) Proximal II (skin) 45 10
27 SCID MMUD (6/8) Proximal 74.2 8
HLH indicates hemophagocytic lymphohistiocytosis; MSD, matched sibling donor;
MUD, matched unrelated donor; LCH, Langerhans cell histiocytosis; GI, gastroint
unrelated donor; IPEX, Immune Dysregulation, polyendocrinopathy, enteropathy,
All chimerism is reported as percent donor, and all time is reported as months po
* Patient included in report by Marsh et al. [6].
y Patient included in report by Marsh et al. [18].of DLIs are available as Supplemental Figure 1a-c. Fifteen
patients (56%) showed at least a 20% improvement in donor
chimerism within 6 weeks of DLI, with 10 patients (37%)
reaching full donor chimerism (99% to 100% donor) at some
point after DLI. Twelve patients (44%) had no signiﬁcant
improvement in donor chimerism after DLI. In patients with
response to DLI, improvement in donor chimerism of at least
20% over pre-DLI donor chimerism was seen at a median ofak Chimerism
ter DLI
Last
Chimerism
Time of Last
Chimerism
Notes
2 70 27
8 100 21 CD34 selected PBSC
boost day 200
7 66 65
7 30 46
8 100 56
0 100 35
9 19 5.5 Death due to recurrent
disease day 165
0 55 30
7 13 30
7 18 37 39% donor T cells at last check
1.6 90 41 CD34 selected PBSC boost 27
months after HSCT
7 26 62 91% donor T cells
0 100 29 Death 38 months post-
transplant, unclear cause
4 28 13 Death at 13 months post-
transplant, unclear cause
3.8 26.7 54 76% donor T cells
0 100 40 Chronic skin GVHD
0 100 40 Chronic skin/mouth GVHD
2.2 100 58 CD34 selected PBSC boost
at day þ150
8 98 9.5 Death due to bacterial
infection day 284
0 98 80
3 0 28 Death due to complications
after second HSCT
7 38 12
5.3 55.8 36
9 98 35
6 14 Second transplant
day þ 109 days
0 100 23
1.6 100 3.5 Death due to fungal disease
at day 117
XLP, X-linked lymphoproliferative disease; PBSC, peripheral blood stem cell;
estinal; CVID, combined variable immunodeﬁciency; MMUD, mismatched
X-linked.
st-transplant.
Figure 1. Response rate by donor source. Percentage of patients achieving at
least a 20% response or complete donor chimerism after DLI appeared to
correlate with donor source, with mismatched unrelated donors having the
highest rate of response and matched sibling donors with no responses.
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reached at a median of 40 days after DLI (range, 14 to 102).
Of the 10 patients reaching full donor chimerism after DLI,
9 had full donor chimerism at their last evaluation or death.
Sevenpatients are alivewith full donor chimerism at amedian
of 23 months post-HSCT, and 1 patient has long-term mixed
donor chimerism (55% donor) at 2.5 years post-HSCT. The 5
patients with incomplete response to DLI reached a peak
donor chimerism ranging from 36% to 93%. Two of these pa-
tients died with mixed donor chimerism. In the 3 remaining
patients with incomplete improvement in donor chimerism,
response was temporary, with a secondary decline in donor
chimerism at a median of 54 days (range, 28 to 95) after last
DLI. Two of these patients underwent second HSCT, with 1
death after the second transplant. The last patient received a
CD34 selected peripheral blood stem cell boost and maintains
donor-predominant chimerism at 27 months post-HSCT.
Twelve patients had no improvement in donor chimerism
after DLI. Eight of these patients continue with mixed donor
chimerism (median 34% [range, 18% to 70%]) at a median
follow-up of 41.5 months post-transplant. Two required CD34
selected peripheral blood stem cell boosts to obtain complete
donor chimerism. A third patient with Langerhans cell his-
tiocytosis died at 165 days post-HSCT of progressive disease,
and a fourth patient had a last documented chimerism of 13%
and is being closely monitored for disease progression.
GVHD after DLI
Ten patients developed acute GVHD after DLI. All these
patients were responders, with 8 reaching full donor
chimerism. In most patients GVHD was mild, with 7 patients
having grade I or II skin GVHD. Three patients developed
grade III gut or liver GVHD after DLI. One patient with severe
GVHD had a 7/8 mismatched unrelated donor and received a
DLI T cell dose of 2  107 CD3/kg. A second patient with a
mismatched unrelated donor developed skin GVHD after
withdrawal of immunosuppression before DLI and subse-
quently developed grade III gastrointestinal GVHD after DLI.
Three patients, 2 with acute GVHD after DLI, had developed
chronic GVHD at last evaluation.
Characteristics of Complete Responders
Of the 10 patients achieving full donor chimerism after
DLI, 5 received 1 DLI, 1 patient received 2 DLIs, 2 patients
received 4 DLIs, and 2 patients received 5 DLIs. Three patients
reaching complete donor chimerism after DLI had received
distal alemtuzumab dosing and the remaining 7 patients
received proximal alemtuzumab dosing. When patients
achieving full donor chimerism after DLI were compared
with patients not achieving full donor chimerism, there was
no difference in chimerism at which DLI was initiated, lowest
chimerism before DLI, initial T cell dose, total T cell dose, and
number of DLIs. DLI tended to occur earlier after transplant in
patients achieving full donor chimerism after DLI (day þ75
for responders, day þ113 days for others), but it did not
achieve statistical signiﬁcance (P ¼ .087). Patients who had a
complete response to DLI also tended to have had ﬁrst
decline in donor chimerism earlier post- transplant,
although this also did not reach statistical signiﬁcance (37
days for ﬁrst loss of chimerism in complete responders, 51
days for all others, P ¼ .053).
Contribution of Donor Source to Response to DLI
Response to DLI by donor source is illustrated in Figure 1.
Seven of the 9 patients (78%) with mismatched unrelateddonors had some response to DLI, with 4 (44%) achieving full
donor chimerism, despite receiving fewer donor lymphocyte
infusions (P ¼ .005) and a lower total T cell dose (P ¼ .015)
when compared with all patients with HLA matched donors.
Eight of 14 patients (57%) with matched unrelated donors
had some response to DLI, with 6 (43%) reaching full donor
chimerism. None of the 4 patients with matched sibling
donors had improvement in donor chimerism after DLI. Two
of 3 patients with grade III GVHD had mismatched unrelated
donors. When patients were sorted by donor type, there was
no signiﬁcant difference in ﬁrst T cell dose between patients
who reached complete donor chimerism after DLI and the
patients who did not. Mismatched unrelated donors did have
earlier loss of donor chimerism (P ¼ .037) and tended to
receive DLI earlier post-HSCT than patients with matched
related or unrelated donors (P ¼ .065).DISCUSSION
With the increased use of reduced-intensity preparative
regimens, pediatric transplant physicians are more often
facing the question of how to manage mixed donor chime-
rism in patients with nonmalignant diseases. Unfortunately,
there is little available literature to guide clinicians, which
may result in reluctance to use DLI until concerns about
inducing GVHD are outweighed by the fear of graft loss. This
report is a single-center retrospective review of all patients
who received DLI for mixed donor chimerism after a widely
used preparative regimen consisting of alemtuzumab, ﬂu-
darabine, and melphalan. To our knowledge this is the ﬁrst
such report of DLI for mixed donor chimerism in a signiﬁcant
cohort of pediatric patients transplanted for nonmalignant
diseases.
This retrospective study demonstrates the relative safety
and efﬁcacy of DLI in improving mixed donor chimerism,
with approximately half of patients having some response to
DLI and 37% with a long-term clinically signiﬁcant
improvement in donor chimerism. Patients who achieved
full donor chimerism tended to continue with full donor
chimerism long term. Although GVHD was common after
DLI, it tended to be mild and not cause long-term morbidity.
Two of 3 patients with severe GVHD had factors (high T cell
dose in mismatched unrelated donor, GVHD before DLI) that
likely increased their risk of severe GVHD.
In this series, donor source was a signiﬁcant factor in
response to DLI. Patients with mismatched unrelated donors
were more likely to respond to DLI despite receiving fewer T
cell infusions and lower total T cell doses. Although it is
possible that the HLA disparity and increased alloreactivity of
the donor lymphocyte increased their efﬁcacy, the earlier
loss of donor chimerism inmismatched unrelated donors is a
confounding variable in this series. The trend to earlier loss of
donor chimerism in complete responders and inmismatched
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underlying early graft loss are potentially more amenable to
therapy with DLI. Despite the confounding factor, these data
suggest that DLI in the setting a mismatched unrelated donor
transplant may be more potent, with an increased likelihood
of response but an increased possibility of severe GVHD. A
lower starting T cell dose for patients with mismatched un-
related donors may be prudent. In contrast, no response to
DLI was seen in any patient with matched sibling donors,
despite the use of relatively high T cell doses. Although the
numbers are small, this suggests DLI may not be effective in
this setting and alternate therapy such as CD34 selected stem
cell boosts may be needed.
A signiﬁcant weakness of this study is its inability to
provide guidance on which patients would beneﬁt from DLI
because of both its retrospective nature and the heteroge-
neity of the patient population. Although it is established
that many patients with nonmalignant diseases are cured of
their disease with mixed donor chimerism [6,9], for most
diagnoses the exact degree of donor chimerism needed to
prevent disease recurrence has not been established and
varies based on disease-speciﬁc cellular defects, further
complicating the decision about when to intervene in mixed
donor chimerism. In addition, the lack of cell subset chime-
rism data makes it impossible to speculate about which pa-
tients with mixed donor chimerism are at risk of proceeding
to graft loss or disease recurrence and which patients may be
likely to respond to DLI. Although several authors have tried
to predict graft loss from cell subset chimerism data, most of
this is in the setting of malignant diseases and may not apply
to this patient population [16,17]. Future studies including
cell subset chimerism data would be particularly helpful in
this heterogeneous patient population to help establish
chimerism thresholds above which disease recurrence is
unlikely and predict which patients are likely to maintain
mixed donor chimerism or progress to graft loss.
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